CDS

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• arthralgia, aromatase inhibitor-induced [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cataracts [Possibly Effective]
• colorectal adenoma [Insufficient Evidence]
• dry eye disease [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• gastritis [Insufficient Evidence]
• GERD [Insufficient Evidence]
• hyperlipidemia [Insufficient Evidence]
• interstitial cystitis [Insufficient Evidence]
• Kashin-Beck disease [Insufficient Evidence]
• knee pain [Insufficient Evidence]
• osteoarthritis [Possibly Effective]
• osteoporosis [Insufficient Evidence]
• overall mortality [Insufficient Evidence]
• psoriasis [Insufficient Evidence]
• skin aging [Insufficient Evidence]
• stroke prevention [Insufficient Evidence]
• temporomandibular disorder [Insufficient Evidence]
• urinary incontinence [Insufficient Evidence]
• UTI [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

arthralgia, aromatase inhibitor-induced

[Insufficient Evidence]

Dose: 1200 mg/day PO divided bid-tid; Info: used with glucosamine sulfate

cataracts

[Possibly Effective]

Dose: 4% eye drops x1 during cataract surgery

dry eye disease

[Insufficient Evidence]

Dose: 1 drop 0.1% in eye(s) qid

exercise-induced muscle soreness

[Insufficient Evidence]

Dose: 300 mg PO bid; Info: used with collagen peptides and hyaluronic acid

interstitial cystitis

[Insufficient Evidence (PO route)]

Dose: 300 mg PO bid

[Insufficient Evidence (intravesical route)]

Dose: 20-40 mL intravesically qmo; Start: 20-40 mL intravesically qwk x4-20wk; Info: 0.2% or 2% solution

Kashin-Beck disease

[Insufficient Evidence]

Dose: 600 mg PO bid; Info: used with or without glucosamine sulfate

knee pain

[Insufficient Evidence]

Dose: 750 mg PO qd

osteoarthritis

[Possibly Effective]

Dose: 600-2000 mg/day PO divided qd-tid; Alt: 400 mg PO tid x3wk, then 400 mg PO bid; Info: commonly used with glucosamine sulfate or glucosamine hydrochloride

skin aging

[Insufficient Evidence]

Dose: 200 mg PO qd; Info: used with collagen peptides and hyaluronic acid

stroke prevention

[Insufficient Evidence]

Dose: 800 mg PO qd

temporomandibular disorder

[Insufficient Evidence]

Dose: 1200 mg PO qd; Info: used with glucosamine sulfate

UTI

[Insufficient Evidence]

Dose: 50 mL (2% solution) intravesically qwk x4wk, then 50 mL intravesically q2-4wk; Alt: 40 mL (0.2% solution) intravesically qwk x6wk, then 40 mL intravesically q2wk x2mo, then 40 mL intravesically q3wk x2mo, then 40 mL intravesically q6wk; Info: used with or without hyaluronic acid